Risk factors analysis and preoperative prediction value of central lymph node metastasis in patients with papillary thyroid cancer and Hashimoto's thyroiditis
SUN Jiajia1, ZHOU Guanglei1, REN Hanxiao2
1. Department of General Surgery, Characteristics Medical Center of Chinese People's Armed Police Force,Tianjin 300162, China; 2. Laboratory Medicine Center, the Second Hospital of Shandong University, Jinan 250033, China
Abstract:Objective To investigate the risk factors and preoperative prediction value of central lymph node metastasis in patients with papillary thyroid carcinoma (PTC) and Hashimoto's thyroiditis (HT).Methods A retrospective analysis was conducted on the basic information, preoperative ultrasound features, and thyroid function of 257 PTC patients with HT admitted to Characters Medical Center of Chinese People's Armed Police Force from January 2020 to December 2022. The patients were divided into two groups based on the presence or absence of central lymph node metastasis. Multivariate logistic regression analysis was used to explore the risk factors affecting central lymph node metastasis.Results Among the 257 PTC patients, 118 (45.91%) cases had central lymph node metastasis. Compared with the patients without central lymph node metastasis, patients with central lymph node metastasis had higher levels of serum TGAb (P=0.000) and lower levels of serum TPOAb (P=0.00). Multivariate logistic regression analysis showed that the tumor location (central OR=2.162,95%CI: 1.892-2.470, P=0.000, lower OR=6.763,95%CI: 3.647-12.53, P=0.000) and the central lymph node margin were irregular (OR=3.535,95% CI: 1.303-9.586, P=0.013); Microcalcification of central lymph nodes (OR=9.916,95%CI:5.264-18.67,P=0.000) and elevated serum TGAb levels (OR=7.124,95%CI:1.560-1.905, P=0.000) were independent risk factors for central lymph node metastasis in PTC with HT patients.Conclusions Preoperative ultrasound features combined with serum TGAb levels can predict central lymph node metastasis in patients with PTC and HT.
孙甲甲, 周广磊, 任含笑. 甲状腺乳头状癌伴桥本甲状腺炎患者中央淋巴结转移的危险因素及术前预测价值[J]. 武警医学, 2023, 34(9): 737-741.
SUN Jiajia, ZHOU Guanglei, REN Hanxiao. Risk factors analysis and preoperative prediction value of central lymph node metastasis in patients with papillary thyroid cancer and Hashimoto's thyroiditis. Med. J. Chin. Peop. Armed Poli. Forc., 2023, 34(9): 737-741.
Pasqual E,Sosa J A,ChenY,et al.Trends in the management of localized papillary thyroid carcinoma in the United States (2000-2018) [J].Thyroid, 2022,32(4):397-410.
Lebbink C A,Links T P,Czarniecka A,et al. 2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma[J].Eur Thyroid J,2022,11(6):e220146.
Song E,Jeon M J, Park S, et al. Influence of coexistent Hashimoto's thyroiditis on the extent of cervical lymph node dissection and prognosis in papillary thyroid carcinoma[J].Clin Endocrinol (Oxf),2018,88(1):123-128.
[7]
Sugitani I,Ito Y,Miyauchi A,et al. Active surveillance versus immediate surgery: questionnaire survey on the current treatment strategy for adult patients with low-risk papillary thyroid microcarcinoma in Japan[J].Thyroid, 2019,29(11):1563-1571.
Wen X,Wang B,Jin Q,et al. Thyroid antibody status is associated with central lymph node metastases in papillary thyroid carcinoma patients with Hashimoto's thyroiditis [J].Ann Surg Oncol,2019,26(6):1751-1758.
Xue S,Han Z,Lu Q,et al. Clinical and ultrasonic risk factors for lateral lymph node metastasis in papillary thyroid microcarcinoma: a systematic review and meta-analysis [J].Front Oncol,2020,10:436.
[14]
Back K,Kim J S,Kim J H,et al. Superior located papillary thyroid microcarcinoma is a risk factor for lateral lymph node metastasis[J].Ann Surg Oncol,2019,26(12):3992-4001.
[15]
Sun W,Lan X,Zhang H,et al.Riskfactors for central lymph node metastasis in cn0 papillary thyroid carcinoma: a systematic review and meta-analysis [J].PLoS One,2015,10(10):e0139021.
[16]
Kim H,Park S Y,Choe J H,et al. Preoperative serum thyroglobulin and its correlation with the burden and extent of differentiated thyroid cancer[J].Cancers (Basel),2020,12(3):625.